# Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

> **NCT03811912** · PHASE2 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** CTP-543
- **DRUG:** CTP-543 Matching Placebo

## Key facts

- **NCT ID:** NCT03811912
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-21
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811912, "Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03811912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*